Get the Weekly Intelligence Brief — top committee picks every Sunday.
GRAL · NASDAQ · STOCK

GRAIL Inc.

Healthcare Updated August 11, 2026
$75.48
52W $29.95 – $118.84
64/100
$3.24B
-7.7
3.25
AI Committee Verdict
Buy
64/100
Conviction: Moderate · 67% agreement · 6 analysts
Moderate

Is GRAL Bullish or Bearish?

Bullish. Innellis AI committee rates GRAIL Inc. (GRAL) Buy with a composite score of 64/100 , based on 6 analysts with 67% agreement. Last updated August 11, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +10.62 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -9.38 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is bollinger bandwidth of 20.8% signals elevated volatility. The committee is constructive but not yet at full conviction.

Bull & Bear Case

Bull Case
  • Price-to-book of 1.3x is a discount to asset value — Value
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
  • ROE of only -16.4% -- cheap may mean cheap for a reason — Value
  • Bollinger bandwidth of 20.8% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 11, 2026
Overall Committee Score
64/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 20%
of 192 Healthcare peers
Value Analyst bullish
60 / 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
+ Price-to-book of 1.3x is a discount to asset value
− ROE of only -16.4% -- cheap may mean cheap for a reason
Growth Analyst bullish
65 / 100 · Low confidence
Strong, accelerating growth with consistent execution
Technical Analyst bullish
69 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Risk Analyst neutral
58 / 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 20.8% signals elevated volatility
Macro Analyst bullish
78 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Open Full Terminal →

Technical Analysis

RSI (14)
60.4
Neutral
MACD Histogram
0.363
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$41.57
Resistance
$75.81
Bollinger %B
0.86
Inside Bands
Price vs Moving Averages
EMA 9
$71.30 Above
EMA 21
$70.10 Above
EMA 50
$67.81 Above
EMA 200
$65.20 Above

Fundamental Analysis

Valuation
100
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio -7.7×
P/B Ratio 1.28×
PEG Ratio -0.25
Dividend Yield 0.00%
52W High $118.84
52W Low $29.95
Quality & Growth
ROE -1584.1%
ROA -1397.5%
Gross Margin -1082.8%
Operating Margin -33840.0%
Revenue Growth YoY
Debt / Equity 0.04
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -7.7 (inexpensive relative to a 15-40x range); Price-to-book of 1.3x; PEG ratio of -0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -15.8%; Return on assets of -14.0%; Net margin of -236.9%; Gross margin of -10.8%; Current ratio of 10.95 (healthy short-term liquidity); Debt-to-equity of 0.04; Free cash flow per share is negative (-6.85); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full GRAL Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore GRAL Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime